Humoral immune responses against minute virus of mice vectors

Lang, Susanne; Giese, Nathalia A.; Rommelaere, Jean; Dinsart, Christiane; Cornelis, Jan J.

doi:10.1002/jgm.940

Cited by 24 publications

(19 citation statements)

References 48 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies also failed to reconstruct the parvovirus-primed immune activation under in vitro conditions, despite clear evidence for immune involvement in the viral anticancer activity in vivo. 13,14 While not showing the CD8 + T cell enrichment seen in spleen, tumor-draining lymph nodes from H-1PV-treated rats comprised a significantly more abundant CD4 + T-cell component, compared to dLN from control animals ( Table 1). Accordingly, the CD4/CD8 ratio was enhanced in dLN (as well as tumors) from infected rats ( Fig.…”

Section: Adoptive Transfer Of Immune Cells From H-mentioning

confidence: 96%

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

Grekova¹,

Aprahamian²,

Giese³

et al. 2010

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

Section: Adoptive Transfer Of Immune Cells From H-mentioning

confidence: 96%

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

Grekova¹,

Aprahamian²,

Giese³

et al. 2010

Cancer Biology & Therapy

Self Cite

View full text Add to dashboard Cite

“…Furthermore, a Phase I clinical trial of H1 parvovirus therapy of glioblastoma multiforme is currently underway in Germany (Geletneky et al, 2010). To date, the study of parvovirus oncolysis of melanoma has been conducted with transplantable mouse models (Bakkouri et al, 2005; Lang et al, 2006; Raykov et al, 2005; Wetzel et al, 2007), and long-established human melanoma cell lines (Dupont et al, 2000). However, no comprehensive survey of a broad range of rodent parvovirus serotypes against freshly-isolated human melanoma cells has been undertaken to date.…”

Section: Introductionmentioning

confidence: 99%

Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses

Vollmers

Tattersall

2013

Virology

View full text Add to dashboard Cite

The rodent parvoviruses are known to be oncoselective, and lytically infect many transformed human cells. Because current therapeutic regimens for metastatic melanoma have a low response rates and have little effect on improving survival, this disease is a prime candidate for novel approaches to therapy, including oncolytic parvoviruses. Screening of low-passage, patient-derived melanoma cell lines for multiplicity-dependent killing by a panel of five rodent parvoviruses, identified LuIII as the most melanoma-lytic. This property was mapped to the LuIII capsid gene, and an efficiently melanomatropic chimeric virus shown to undergo three types of interaction with primary human melanoma cells: 1) complete lysis of cultures infected at very low multiplicities; 2) acute killing resulting from viral protein synthesis and DNA replication, without concomitant expansion of the infection, due to failure to export progeny virions efficiently; or 3) complete resistance that operates at an intracellular step following virion uptake, but preceding viral transcription.

show abstract

“…The virus in the bloodstream could be inactivated by complement proteins 4,5 or the reticuloendothelial system, 6,7 but the most restrictive barrier to effective treatment is the acquired immunity to repeated infections due to neutralizing antibodies (nAbs) (Figure 1a). [8][9][10][11] Several approaches to reduce the negative impact of adaptive immunity on OVs have been developed, such as the use OVs with cyclophosphamide as an immunosuppressive drug, 12 polymer-coated OVs to shield the virus from its nAbs [13][14][15] and virus-preinfected T cells or syngeneic carrier cells that act as delivery vehicles to tumor sites and shielding agents. [16][17][18][19] Polymer coating and cell-based methodologies increase the virus stability in blood but significantly decrease the uptake of OVs by tumor cells due to blocking virus-cell receptor interactions.…”

Section: Introductionmentioning

confidence: 99%

Aptamer-Facilitated Protection of Oncolytic Virus From Neutralizing Antibodies

Muharemagic¹,

Zamay²,

Ghobadloo³

et al. 2016

SMR

View full text Add to dashboard Cite

Oncolytic viruses promise to significantly improve current cancer treatments through their tumor-selective replication and multimodal attack against cancer cells. However, one of the biggest setbacks for oncolytic virus therapy is the intravenous delivery of the virus, as it can be cleared from the bloodstream by neutralizing antibodies before it reaches the tumor cells. We have selected DNA aptamers against an oncolytic virus, vesicular stomatitis virus, using a competitive binding approach, as well as against the antigen binding fragment (Fab) of antivesicular stomatitis virus polyclonal antibodies, in order to shield the virus from nAbs and enhance its in vivo survival. We used flow cytometry to identify these aptamers and evaluated their efficiency to shield vesicular stomatitis virus in a cell-based plaque forming assay. These oligonucleotides were then modified to obtain multivalent binders, which led to a decrease of viral aggregation, an increase in its infectivity and an increase in its stability in serum. The aptamers were also incubated in nondiluted serum, showing their effectiveness under conditions mimicking those in vivo. With this approach, we were able to increase viral infectivity by more than 70% in the presence of neutralizing antibodies. Thus, this method has the potential to enhance the delivery of vesicular stomatitis virus through the bloodstream without compromising the patient's immune system.

show abstract

Humoral immune responses against minute virus of mice vectors

Abstract: Neutralizing antibodies impede the effectiveness of a subsequent virus administration, but can be overcome by pseudotyping.

Cited by 24 publications

References 48 publications

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent

Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses

Aptamer-Facilitated Protection of Oncolytic Virus From Neutralizing Antibodies

Contact Info

Product

Resources

About